Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe.
Sponsors
Giannina Gaslini Institute For Scientific Hospitalization And Care, Stichting Radboud University Medical Center, Assistance Publique Hopitaux De Paris, Hellenic Institute For The Study Of Sepsis, Universitaetsklinikum Heidelberg AöR
Conditions
Acute respiratory distress syndrome (ARDS)Cystic fibrosisFamilial Mediterranean Fever (FMF)Inflammatory response following human endotoxemia in healthy volunteersKawasaki diseaseMen and women over 18 years of age with renal failure renal failure stages 3b/4/5PEDIATRIC ACUTE MYOCARDITISPost-Acute COVID Syndrome (PACS)
Phase 1
Phase 2
Safety and efficacy of anakinra treatment for patients with persistent respiratory symptoms post acute covid and immune system activation: the PRECISION double-blind, randomized clinical trial
RecruitingCTIS2023-508123-12-00
Start: 2023-11-03Target: 302Updated: 2025-05-20
A phase IIa, randomized, placebo-controlled, double-blind,
cross-over study to evaluate safety and efficacy of
subcutaneous administration of anakinra in patients with
cystic fibrosis (ANAKIN)
RecruitingCTIS2023-510376-31-00
Start: 2022-10-05Target: 60Updated: 2024-05-16
Immunomodulatory effects of dexamethasone, tocilizumab and anakinra during experimental human endotoxemia: the DEDICATE-LPS study
Active, not recruitingCTIS2023-506556-24-00
Start: 2024-10-24Target: 52Updated: 2025-04-28
Efficacy and safety of anakinra in non-COVID-19 related ARDS. ESKA study.
Not yet recruitingCTIS2024-518125-15-00
Target: 36Updated: 2024-11-18
Phase 3
Therapeutic approach in Colchicine-resistant Recurrent pEricarditis in children: an open-label randomized trial comparing Anakinra vs sTEroids
RecruitingCTIS2023-504756-96-00
Start: 2024-03-22Target: 48Updated: 2025-07-21
Randomized controlled trial in patients on long-term colchicine with colchicine-resistant familial Mediterranean fever (FMF) to evaluate the efficacy of on-demand Anakinra treatment for painful attacks in patients who refuse continuous daily therapy (KIN-ATTACK-FMF).
RecruitingCTIS2023-506721-11-00
Start: 2024-06-04Target: 50Updated: 2024-10-30
ANA4CKD - Randomized multicenter double-blind controlled trial comparing anakinra to prednisone for gout flare in patients with chronic kidney disease stage 4-5 or kidney transplantation
CompletedCTIS2024-514347-28-00
Start: 2022-06-02End: 2025-02-12Target: 234Updated: 2024-10-21
ANACOMP. A RANDOMIZED PHASE III MULTICENTER TRIAL COMPARING THE EFFICACY AND SAFETY OF ANAKINRA VERSUS INTRAVENOUS IMMUNOGLOBULIN (IVIG) RETREATMENT, IN PATIENTS WITH KAWASAKI DISEASE WHO FAILED TO RESPOND TO INITIAL STANDARD IVIG TREATMENT
SuspendedCTIS2024-516244-25-00
Start: 2024-11-06Target: 84Updated: 2025-12-30
ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS. ANAPEM
Not yet recruitingCTIS2025-521478-32-00
Target: 110Updated: 2025-09-04